2022-501661-47-00CompletedPhase 2
INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Sept 2025
Brief summary (registry, in English)
To provide continued treatment and evaluation of safety in participants who are receiving clinical benefit with an itacitinib-based therapy in an Incyte-sponsored clinical study.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 10 Nov 2022
- Start date
- 23 Aug 2023
- Lead sponsor
- Incyte Corp.
- Diseases
- Myeloproliferative neoplasms
- EU CT number
- 2022-501661-47-00
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 12
- 7 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Able to access itacitinib therapy commercially.
- Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.
Other
- Pregnant or breastfeeding women.
- Any personal status that would prohibit clinical trial participation under local regulations.
Who the study is looking for
- Currently enrolled and receiving treatment in an Incyte-sponsored itacitinib (INCB 39110)-based clinical study (parent protocol).
- Currently tolerating treatment as defined by the parent protocol.
- Currently receiving clinical benefit from itacitinib-based treatment, as determined by the investigator.
- Has demonstrated compliance, as assessed by the investigator, with the parent protocol requirements.
- Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this Protocol.
- Willingness to avoid pregnancy or fathering children based on criteria in Section 5. l .
- Ability to comprehend and willingness to sign an ICF.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ordensklinikum Linz GmbH | Linz | Austria | Completed |
| UZ Leuven | Leuven | Belgium | Completed |
| Martin-Luther-Universitaet Halle-Wittenberg | Halle (Saale) | Germany | Completed |
| Universitaetsklinikum Mannheim GmbH | Mannheim | Germany | Completed |
| Hospital Universitario Ramón y Cajal | Madrid | Spain | Completed |
| University General Hospital Attikon | Athens | Greece | Completed |
| Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona | Salerno | Italy | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.